tiprankstipranks
Trending News
More News >
Shanghai Haohai Biological Technology Co., Ltd. Class H (HK:6826)
:6826
Hong Kong Market
Advertisement

Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Shanghai Haohai Biological Technology Co., Ltd. Class H has a market cap or net worth of HK$11.94B. The enterprise value is HK$8.84B.
Market CapHK$11.94B
Enterprise ValueHK$8.84B

Share Statistics

Shanghai Haohai Biological Technology Co., Ltd. Class H has 39,141,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,141,840
Owned by Insiders
Owned by Institutions

Financial Efficiency

Shanghai Haohai Biological Technology Co., Ltd. Class H’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 6.11%.
Return on Equity (ROE)0.08
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)6.11%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee1.24M
Profits Per Employee216.21K
Employee Count2,156
Asset Turnover0.38
Inventory Turnover1.65

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio13.9
PS Ratio0.00
PB Ratio2.08
Price to Fair Value1.05
Price to FCF25.01
Price to Operating Cash Flow16.67
PEG Ratio-2.82

Income Statement

In the last 12 months, Shanghai Haohai Biological Technology Co., Ltd. Class H had revenue of 2.68B and earned 420.45M in profits. Earnings per share was 1.80.
Revenue2.68B
Gross Profit1.87B
Operating Income496.29M
Pretax Income466.14M
Net Income420.45M
EBITDA665.04M
Earnings Per Share (EPS)1.80

Cash Flow

In the last 12 months, operating cash flow was 440.55M and capital expenditures -185.75M, giving a free cash flow of 254.80M billion.
Operating Cash Flow440.55M
Free Cash Flow254.80M
Free Cash Flow per Share6.51

Dividends & Yields

Shanghai Haohai Biological Technology Co., Ltd. Class H pays an annual dividend of HK$0.655, resulting in a dividend yield of 4.1%
Dividend Per ShareHK$0.655
Dividend Yield4.1%
Payout Ratio45.59%
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.95
52-Week Price Change-14.95%
50-Day Moving Average25.24
200-Day Moving Average26.77
Relative Strength Index (RSI)57.07
Average Volume (3m)572.88K

Important Dates

Shanghai Haohai Biological Technology Co., Ltd. Class H upcoming earnings date is ―, ―.
Last Earnings Date
Next Earnings Date
Ex-Dividend DateJun 17, 2025

Financial Position

Shanghai Haohai Biological Technology Co., Ltd. Class H as a current ratio of 4.22, with Debt / Equity ratio of 7.98%
Current Ratio4.22
Quick Ratio3.66
Debt to Market Cap0.07
Net Debt to EBITDA-3.28
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Shanghai Haohai Biological Technology Co., Ltd. Class H has paid 89.90M in taxes.
Income Tax89.90M
Effective Tax Rate0.19

Enterprise Valuation

Shanghai Haohai Biological Technology Co., Ltd. Class H EV to EBITDA ratio is 5.49, with an EV/FCF ratio of 12.91.
EV to Sales1.36
EV to EBITDA5.49
EV to Free Cash Flow12.91
EV to Operating Cash Flow5.63

Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd. Class H has HK$2.66B in cash and marketable securities with ¥452.51M in debt, giving a net cash position of -HK$2.21B billion.
Cash & Marketable SecuritiesHK$2.66B
Total Debt¥452.51M
Net Cash-HK$2.21B
Net Cash Per Share-HK$56.43
Tangible Book Value Per ShareHK$20.54

Margins

Gross margin is 67.28%, with operating margin of 18.52%, and net profit margin of 15.69%.
Gross Margin67.28%
Operating Margin18.52%
Pretax Margin17.40%
Net Profit Margin15.69%
EBITDA Margin24.82%
EBIT Margin18.07%

Analyst Forecast

The average price target for Shanghai Haohai Biological Technology Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-1.81%
EPS Growth Forecast-3.79%

Scores

Smart Score3
AI Score73
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis